Diabetes Pro Quarterly - Spring 2021 - 14

Clinical News

Clinical Diabetes Video Series: Combination Injectable Therapy in
Patients With Type 2 Diabetes
The editors of Clinical Diabetes, the American Diabetes
Association's journal for primary and point-of-care providers,
are excited to announce the publication of a digital program
titled " Rationale for the Use of Combination Injectable
Therapy in Patients With Type 2 Diabetes Who Have
High A1C (≥9%) and/or Long Duration (>8 Years). " In this
short video series, Vivian A. Fonseca, MD, FRCP, Minisha
Sood, MD, FACE, and Rodolfo J. Galindo, MD, discuss
the pathophysiological changes that occur during the
progression of type 2 diabetes, with a particular focus on the
key role of declining β-cell function, as well as the clinical
characteristics-long duration of type 2 diabetes and A1C
≥9%-that are indicative of diminishing β-cell function.
Drs. Fonseca, Sood, and Galindo also review the clinical
data supporting the use of available treatment options for
these individuals, consistent with current diabetes treatment
guidelines, and specifically examine the role of fixed-ratio
combination therapies of a basal insulin and a glucagon-like
peptide 1 receptor agonist.

The videos and an executive summary of the
panel's recommendation are available on the Clinical
Diabetes website.
This is the second in an ongoing series of digital
programs published in Clinical Diabetes. In the first
video series, " Effective Initiation and Treatment With
Basal Insulin in People With Type 2 Diabetes: Focus on
Mitigating Hypoglycemia in Patients at Increased Risk, "

moderated by John Anderson, MD, experts discuss
approaches to optimizing basal insulin initiation and
treatment in people with type 2 diabetes, including those
at high risk such as individuals with renal impairment and
older adults, with a focus on reaching A1C goals while
mitigating the risk for hypoglycemia. Financial support
for both digital programs was provided by Sanofi.
Sign up for Clinical Diabetes e-Alerts to stay on top
of the latest trends and innovations in diabetes care
and treatment.

The 35th Annual Clinical Conference is
the source for leading-edge treatment
updates and the latest information in
diabetes.
The 35th Annual Clinical Conference will be held virtually from June 10-13, 2021. Earn 20.5 CE credits.
Join your colleagues and diabetes experts for presentations and discussions on cutting-edge clinical
research in diabetes. With its multidisciplinary focus, the education offered at the ADA's Clinical
Conference draws attendees from across the healthcare spectrum, from across the nation and
around the world. The course will cover the latest clinical research translated into evidence-based
treatment strategies to improve outcomes in your patients with diabetes.
The 35th Annual Clinical Conference is designed specifically for primary care physicians, physician
assistants, nurse practitioners, pharmacists, nurses, dietitians, psychologists, social workers, certified
diabetes care and education specialists and other healthcare professionals who care for patients with
diabetes, at risk for diabetes, and who manage diabetes related complications.
All prerecorded sessions will be released during the original scheduled times over the 4-day meeting, and
all registered attendees will receive unlimited access to all virtual content for 30 days after the meeting.
Registration is open now. Visit professional.diabetes.org/cc for more information.
Product Theater sponsored by Abbott Diabetes Care, AstraZeneca Pharmaceuticals LP, Bayer
Healthcare Pharmaceuticals, and Lilly USA, LLC

DiabetesPro Quarterly | SPRING 2021

Diabetes Pro Quarterly - Spring 2021

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Spring 2021